Braunschweig, December 04, 2020 – YUMAB spin-off CORAT Therapeutics is developing a human antibody for the treatment of COVID-19 patients. Today, the company published the structure of this antibody and the history of its development, performed in the laboratories of Prof. Michael Hust and Prof. Stefan Duebel of the Technical University of Braunschweig in collaboration with YUMAB.
Contact
YUMAB GmbH
Dr. Thomas Schirrmann, CEO
Phone: +49-531 481170-0
Email: info@yumab.com
CORAT Therapeutics GmbH
Dr. Andreas Herrmann, Managing Director
Phone: +49-152 2404 7488
Email: hello@corat-therapeutics.com
YUMAB GmbH
Science Campus Braunschweig-Süd
Inhoffenstr. 7
38124 Braunschweig – Germany
Phone: +49 531 481170-0
Fax: +49-531 481170-17
